Amélie Marsot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amélie Marsot has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Nicolas Simon
Department of Clinical Pharmacology, APHM, Institut de Neurosciences de la Timone, UMR7289, CNRS, Hôpital Sainte Marguerite, CAP-TV, Aix Marseille University, France
7 shared publications Romain Guilhaumou
Service de Pharmacologie Clinique et Pharmacovigilance, Assistance Publique des Hôpitaux de Marseille Marseille France
7 shared publicationsOlivier Blin
Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, Marseille
5 shared publications- Benoît Crevier
Department of Pharmacy Centre intégré de santé et de services sociaux de la Montérégie‐Centre Greenfield Park Québec Canada
4 shared publications - Ibrahim El-Haffaf
Université de Montréal
4 shared publications Julien Dupouey
Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, Marseille
4 shared publications
Latest Publications
- 21 October 2026
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 40 (6) , e70116
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin‐Tazobactam for the Population With Obesity: An Open Randomized Controlled Feasibility Study (TAZO‐OBESITY Trial)
Background: Observational studies report that prolonged infusions of piperacillin‐tazobactam may enable the achievement of an optimal clinically targeted free drug concentration above the minimum inhibitory concentration (fT > MIC). Objectives: This study aimed to assess the feasibility of a randomized controlled trial (RCT) comparing standard to prolonged infusions of piperacillin‐tazobactam in the obese population. Methods: In this open‐label RCT, patients with a body mass index (BMI) of 30 kg/m 2 or higher who initiated piperacillin‐tazobactam were recruited and randomly assigned to receive either standard or prolonged infusions of the antibiotic. Feasibility and safety outcomes were assessed. A blood sample was collected 24 h after the intervention to measure total piperacillin concentrations, with an exploratory aim of determining the proportion of patients who achieved 100% fT > MIC. Results: A total of 45 patients were recruited at a rate of 7.2 patients per month with a consent rate of 42.1%, achieving these feasibility objectives. Adherence to blood sampling was 77.8%, below the 80% objective. On an exploratory basis, the proportion of patients who achieved 100% fT > MIC 24 h postintervention was 64.3% in the prolonged‐infusion group and 55.6% in the standard‐infusion group ( p = 0.725). There was no significant difference in the safety outcomes ( p = 0.756). Conclusion: This first RCT evaluating prolonged infusions of piperacillin‐tazobactam in the obese population demonstrated the feasibility of the protocol. Although not statistically significant, the results suggest a favorable trend for fT > MIC attainment and no safety signal for prolonged infusions and support the conduct of a larger scale RCT. Trial Registration: Clinical trial registration: NCT #06690905
- 21 October 2026
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 40 (6) , e70116
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin‐Tazobactam for the Population With Obesity: An Open Randomized Controlled Feasibility Study (TAZO‐OBESITY Trial)
Background: Observational studies report that prolonged infusions of piperacillin‐tazobactam may enable the achievement of an optimal clinically targeted free drug concentration above the minimum inhibitory concentration (fT > MIC). Objectives: This study aimed to assess the feasibility of a randomized controlled trial (RCT) comparing standard to prolonged infusions of piperacillin‐tazobactam in the obese population. Methods: In this open‐label RCT, patients with a body mass index (BMI) of 30 kg/m 2 or higher who initiated piperacillin‐tazobactam were recruited and randomly assigned to receive either standard or prolonged infusions of the antibiotic. Feasibility and safety outcomes were assessed. A blood sample was collected 24 h after the intervention to measure total piperacillin concentrations, with an exploratory aim of determining the proportion of patients who achieved 100% fT > MIC. Results: A total of 45 patients were recruited at a rate of 7.2 patients per month with a consent rate of 42.1%, achieving these feasibility objectives. Adherence to blood sampling was 77.8%, below the 80% objective. On an exploratory basis, the proportion of patients who achieved 100% fT > MIC 24 h postintervention was 64.3% in the prolonged‐infusion group and 55.6% in the standard‐infusion group ( p = 0.725). There was no significant difference in the safety outcomes ( p = 0.756). Conclusion: This first RCT evaluating prolonged infusions of piperacillin‐tazobactam in the obese population demonstrated the feasibility of the protocol. Although not statistically significant, the results suggest a favorable trend for fT > MIC attainment and no safety signal for prolonged infusions and support the conduct of a larger scale RCT. Trial Registration: Clinical trial registration: NCT #06690905
- 6 February 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (3) , 347-376
β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses
Obesity is becoming more prevalent, and it significantly alters drug pharmacokinetics (PK), potentially impacting the efficacy and safety of β-lactam antibiotics. Population pharmacokinetic (popPK) modeling plays a crucial role in optimizing dosing strategies, yet there is variability in how these models account for obesity-related physiological changes. This review aims to synthesize published popPK studies on β-lactams in obese populations, highlighting key findings and modeling approaches. A literature review was conducted to identify popPK studies evaluating β-lactam antibiotics in obese individuals. Relevant databases were searched for studies reporting PK parameters, covariates, and dosing recommendations. A total of 24 studies met the predefined selection criteria. The majority employed two-compartment models with creatinine clearance (CLCR) and total body weight (TBW) as the most common covariates for clearance (CL) and volume of distribution (Vd). Estimated PK parameters differed within the same β-lactam, which indicates that obesity influences the PK of β-lactams, though the extent of its impact differs based on the specific drug, patient characteristics, and selected covariates. This review highlights the key aspects of popPK models in obese populations treated with β-lactams. Despite the growing prevalence of obesity, its influence on β-lactam antibiotics remains uncertain.
- 6 February 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (3) , 347-376
β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses
Obesity is becoming more prevalent, and it significantly alters drug pharmacokinetics (PK), potentially impacting the efficacy and safety of β-lactam antibiotics. Population pharmacokinetic (popPK) modeling plays a crucial role in optimizing dosing strategies, yet there is variability in how these models account for obesity-related physiological changes. This review aims to synthesize published popPK studies on β-lactams in obese populations, highlighting key findings and modeling approaches. A literature review was conducted to identify popPK studies evaluating β-lactam antibiotics in obese individuals. Relevant databases were searched for studies reporting PK parameters, covariates, and dosing recommendations. A total of 24 studies met the predefined selection criteria. The majority employed two-compartment models with creatinine clearance (CLCR) and total body weight (TBW) as the most common covariates for clearance (CL) and volume of distribution (Vd). Estimated PK parameters differed within the same β-lactam, which indicates that obesity influences the PK of β-lactams, though the extent of its impact differs based on the specific drug, patient characteristics, and selected covariates. This review highlights the key aspects of popPK models in obese populations treated with β-lactams. Despite the growing prevalence of obesity, its influence on β-lactam antibiotics remains uncertain.
- 3 December 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1223-1232
A simulation study to assess the influence of population pharmacokinetic model selection on initial dosing recommendations of vancomycin in neonates
Aims: The accuracy of model‐informed precision dosing largely depends on selecting the most appropriate population pharmacokinetic (popPK) model from many available options. This study aims to evaluate the concordance of optimal initial simulated doses among various vancomycin popPK models developed in neonates and to explore the role of predictive performance in explaining the variability in probability of target attainment (PTA).Methods: A virtual neonatal patient population was created and 26 previously externally evaluated vancomycin popPK models were used to simulate 5 different dosing regimens. For each simulated scenario, the area under the concentration–time curve and PTA were calculated to assess the agreement on optimal initial doses across the 26 models. A multiple regression was performed to explore the impact of the models' predictive performance on PTA.Results: For most models (15/26), there was an agreement on the optimal dosing regimen. The highest PTA being achieved by the model with the best a priori predictive performance. The multiple regression model significantly predicted mean ln‐transformed PTA, with F(2, 23) = 5.406 and P = .010, yielding an adjusted R2 of .21. PTA was significantly influenced by imprecision (P = .048) but not bias (P = .469).Conclusion: In conclusion, our study demonstrated that, despite the variability in bias and imprecision, there was a consensus on the initial optimal doses for the majority of models; however, models with superior a priori predictive performance yielded higher PTA values. Bias and imprecision alone only seem to predict a small proportion of the variability in PTA, with imprecision having a more pronounced effect.
- 3 December 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1223-1232
A simulation study to assess the influence of population pharmacokinetic model selection on initial dosing recommendations of vancomycin in neonates
Aims: The accuracy of model‐informed precision dosing largely depends on selecting the most appropriate population pharmacokinetic (popPK) model from many available options. This study aims to evaluate the concordance of optimal initial simulated doses among various vancomycin popPK models developed in neonates and to explore the role of predictive performance in explaining the variability in probability of target attainment (PTA).Methods: A virtual neonatal patient population was created and 26 previously externally evaluated vancomycin popPK models were used to simulate 5 different dosing regimens. For each simulated scenario, the area under the concentration–time curve and PTA were calculated to assess the agreement on optimal initial doses across the 26 models. A multiple regression was performed to explore the impact of the models' predictive performance on PTA.Results: For most models (15/26), there was an agreement on the optimal dosing regimen. The highest PTA being achieved by the model with the best a priori predictive performance. The multiple regression model significantly predicted mean ln‐transformed PTA, with F(2, 23) = 5.406 and P = .010, yielding an adjusted R2 of .21. PTA was significantly influenced by imprecision (P = .048) but not bias (P = .469).Conclusion: In conclusion, our study demonstrated that, despite the variability in bias and imprecision, there was a consensus on the initial optimal doses for the majority of models; however, models with superior a priori predictive performance yielded higher PTA values. Bias and imprecision alone only seem to predict a small proportion of the variability in PTA, with imprecision having a more pronounced effect.
- Open Access
- 15 November 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (12) , 907-919
External evaluation of neonatal vancomycin population pharmacokinetic models: Moving from first‐order equations to Bayesian‐guided therapeutic monitoring
Introduction: Guidelines for vancomycin therapeutic monitoring recommend using a Bayesian approach with a population pharmacokinetic model to estimate the 24 h area under the concentration‐time curve over first‐order equations. Thus, we performed an external evaluation of population pharmacokinetic models of vancomycin in neonates and compared Bayesian results with those observed in clinical practice via pharmacokinetic equations to improve therapeutic monitoring by proposing optimized initial dosing nomograms and assessing the feasibility of reduced blood sampling strategies using the most predictive models.Methods: Models were identified from the literature and evaluated via an external neonatal population. A priori predictive performance was first assessed by prediction‐based diagnostics, then by simulation‐based diagnostics and a posteriori analyses only if deemed satisfactory; model‐informed vancomycin exposure was also compared with reference first‐order pharmacokinetic equations. The best‐performing models were ultimately subjected to Monte Carlo simulations to develop new initial dosing nomograms offering the highest probability of achieving therapeutic target.Results: A total of 28 population pharmacokinetic models were evaluated in the external dataset, which includes 72 neonates and 380 vancomycin concentrations. Eleven models had an adequate predictive performance with bias ≤ ± 15% and imprecision 30%, while the Bayesian approach yielded over 75% agreement with reference exposure values in most cases. Nonetheless, Capparelli et al. and Mehrotra et al. models performed the best overall, showing the lowest imprecisions of 16.8% and 16.9%, respectively; both models recommended higher dosage regimens than the theoretical nomogram currently applied to favor therapeutic target attainment.Discussion: We externally evaluated numerous neonatal population pharmacokinetic models of vancomycin and used the most predictive ones to advocate new initial dosing nomograms. Clinical implementation of the Bayesian approach could reduce the time needed to reach therapeutic target and limit the number of blood samples in newborns compared with traditional pharmacokinetic equations.
- 15 November 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (12) , 907-919
Open AccessExternal evaluation of neonatal vancomycin population pharmacokinetic models: Moving from first‐order equations to Bayesian‐guided therapeutic monitoring
Introduction: Guidelines for vancomycin therapeutic monitoring recommend using a Bayesian approach with a population pharmacokinetic model to estimate the 24 h area under the concentration‐time curve over first‐order equations. Thus, we performed an external evaluation of population pharmacokinetic models of vancomycin in neonates and compared Bayesian results with those observed in clinical practice via pharmacokinetic equations to improve therapeutic monitoring by proposing optimized initial dosing nomograms and assessing the feasibility of reduced blood sampling strategies using the most predictive models.Methods: Models were identified from the literature and evaluated via an external neonatal population. A priori predictive performance was first assessed by prediction‐based diagnostics, then by simulation‐based diagnostics and a posteriori analyses only if deemed satisfactory; model‐informed vancomycin exposure was also compared with reference first‐order pharmacokinetic equations. The best‐performing models were ultimately subjected to Monte Carlo simulations to develop new initial dosing nomograms offering the highest probability of achieving therapeutic target.Results: A total of 28 population pharmacokinetic models were evaluated in the external dataset, which includes 72 neonates and 380 vancomycin concentrations. Eleven models had an adequate predictive performance with bias ≤ ± 15% and imprecision 30%, while the Bayesian approach yielded over 75% agreement with reference exposure values in most cases. Nonetheless, Capparelli et al. and Mehrotra et al. models performed the best overall, showing the lowest imprecisions of 16.8% and 16.9%, respectively; both models recommended higher dosage regimens than the theoretical nomogram currently applied to favor therapeutic target attainment.Discussion: We externally evaluated numerous neonatal population pharmacokinetic models of vancomycin and used the most predictive ones to advocate new initial dosing nomograms. Clinical implementation of the Bayesian approach could reduce the time needed to reach therapeutic target and limit the number of blood samples in newborns compared with traditional pharmacokinetic equations.
- Open Access
- 9 November 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (3) , 856-865
External evaluation of intravenous vancomycin population pharmacokinetic models in adults receiving high‐flux intermittent haemodialysis
Aims: Patients undergoing haemodialysis (HD) are at greater risk of methicillin‐resistant Staphylococcus aureus infections requiring intravenous vancomycin. Close vancomycin therapeutic drug monitoring is warranted in HD patients as renal clearance is the primary elimination pathway. Clinically, population pharmacokinetics (popPK) model‐informed dosing is commonly used. This study aimed to perform an external evaluation of published vancomycin popPK models developed for adults undergoing high‐flux intermittent HD, and to create a dosing nomogram derived from the model that performed best.Methods: A literature review was conducted through PubMed and EMBASE to identify relevant popPK models. an external dataset was collected retrospectively from patients of 2 healthcare centres in Quebec, Canada. Selected models were implemented in NONMEM (v7.5; ICON Development Solutions). Predictive performance was assessed through prediction and simulation‐based diagnostics.Results: In total, 2386 vancomycin concentrations were collected from 274 patients and 476 antibiotic courses. Four vancomycin popPK models were selected for evaluation. None of the models demonstrated overall satisfactory or clinically acceptable predictive performance. Nonetheless, Bae et al.’s model performed best with a median prediction error of 16.25% and median absolute prediction error of 34.66%. Different predictive performance was also observed for vancomycin concentrations from samples collected during and between HD sessions.Conclusion: All evaluated models presented poor overall predictive performance. Further studies are required, through existing popPK model parameter re‐estimation or new model development, to adequately describe vancomycin pharmacokinetics for our high‐flux intermittent HD patient cohort.
- 9 November 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (3) , 856-865
Open AccessExternal evaluation of intravenous vancomycin population pharmacokinetic models in adults receiving high‐flux intermittent haemodialysis
Aims: Patients undergoing haemodialysis (HD) are at greater risk of methicillin‐resistant Staphylococcus aureus infections requiring intravenous vancomycin. Close vancomycin therapeutic drug monitoring is warranted in HD patients as renal clearance is the primary elimination pathway. Clinically, population pharmacokinetics (popPK) model‐informed dosing is commonly used. This study aimed to perform an external evaluation of published vancomycin popPK models developed for adults undergoing high‐flux intermittent HD, and to create a dosing nomogram derived from the model that performed best.Methods: A literature review was conducted through PubMed and EMBASE to identify relevant popPK models. an external dataset was collected retrospectively from patients of 2 healthcare centres in Quebec, Canada. Selected models were implemented in NONMEM (v7.5; ICON Development Solutions). Predictive performance was assessed through prediction and simulation‐based diagnostics.Results: In total, 2386 vancomycin concentrations were collected from 274 patients and 476 antibiotic courses. Four vancomycin popPK models were selected for evaluation. None of the models demonstrated overall satisfactory or clinically acceptable predictive performance. Nonetheless, Bae et al.’s model performed best with a median prediction error of 16.25% and median absolute prediction error of 34.66%. Different predictive performance was also observed for vancomycin concentrations from samples collected during and between HD sessions.Conclusion: All evaluated models presented poor overall predictive performance. Further studies are required, through existing popPK model parameter re‐estimation or new model development, to adequately describe vancomycin pharmacokinetics for our high‐flux intermittent HD patient cohort.
- Open Access
- 5 October 2024
- Published by Wiley
Exposure levels and target attainment of meropenem in adult patients admitted to the intensive care unit: a prospective observational study
Aim: Patients hospitalized in the intensive care units (ICU) with serious infections require rapid and optimal broad-spectrum antibiotic regimens to ensure favorable outcomes. The purpose of this study was to evaluate the exposure and pharmacokinetic/pharmacodynamic target attainment of meropenem in critically ill patients. Methods: We conducted a prospective observational study in two Canadian intensive care units (ICU) from January 2021 to December 2023. We included adult patients admitted in the ICU who received meropenem. On study day 1, 4 and 7 of antimicrobial therapy, three blood samples were collected: 1 h after meropenem dose administration, at the middle and at the end of the dosing interval. Samples were analyzed by ultra-high performance liquid chromatography with diode array detector. The pharmacokinetic profile of meropenem was evaluated, as well as the attainment of plasma concentrations above minimum inhibitory concentrations of 2, 4 and 8 mg/L at mid-point and at trough. Results: We enrolled twenty-eight patients and analyzed 167 meropenem concentrations. We observed large interindividual variability, with up to a 58-fold difference, but intra-patient variability was low. At mid-point, 52% of concentrations were below the target concentration of 8 mg/L, while this proportion increased to 73% for trough concentrations. Patients who failed to reach therapeutic concentrations all had normal to augmented renal clearance. Conclusion: The majority of ICU patients who received meropenem were underexposed for a target concentration of 8 mg/L, with significant interindividual variability. A more personalized approach such as TDM may help achieve optimal target concentration and potentially improve clinical outcomes.
- 5 October 2024
- Published by Wiley
Open AccessExposure levels and target attainment of meropenem in adult patients admitted to the intensive care unit: a prospective observational study
Aim: Patients hospitalized in the intensive care units (ICU) with serious infections require rapid and optimal broad-spectrum antibiotic regimens to ensure favorable outcomes. The purpose of this study was to evaluate the exposure and pharmacokinetic/pharmacodynamic target attainment of meropenem in critically ill patients. Methods: We conducted a prospective observational study in two Canadian intensive care units (ICU) from January 2021 to December 2023. We included adult patients admitted in the ICU who received meropenem. On study day 1, 4 and 7 of antimicrobial therapy, three blood samples were collected: 1 h after meropenem dose administration, at the middle and at the end of the dosing interval. Samples were analyzed by ultra-high performance liquid chromatography with diode array detector. The pharmacokinetic profile of meropenem was evaluated, as well as the attainment of plasma concentrations above minimum inhibitory concentrations of 2, 4 and 8 mg/L at mid-point and at trough. Results: We enrolled twenty-eight patients and analyzed 167 meropenem concentrations. We observed large interindividual variability, with up to a 58-fold difference, but intra-patient variability was low. At mid-point, 52% of concentrations were below the target concentration of 8 mg/L, while this proportion increased to 73% for trough concentrations. Patients who failed to reach therapeutic concentrations all had normal to augmented renal clearance. Conclusion: The majority of ICU patients who received meropenem were underexposed for a target concentration of 8 mg/L, with significant interindividual variability. A more personalized approach such as TDM may help achieve optimal target concentration and potentially improve clinical outcomes.
- 16 September 2024
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 49 (6) , 677-687
Vancomycin in Pediatric Patients with Cystic Fibrosis: Dose Optimization Using Population Pharmacokinetic Approach
Background An increase in Staphylococcus aureus infections has been reported in pediatric patients with cystic fibrosis (CF) over the last few years. This pathogen is commonly treated with vancomycin, an antibiotic for which therapeutic drug monitoring (TDM) is recommended. Updated guidelines were recently published regarding new targets of exposure for the TDM of vancomycin through a Bayesian approach, using population pharmacokinetic (popPK) models. Objectives This study aims to assess the predictive performance of vancomycin popPK models in pediatric patients with CF and to recommend optimal initial dosing regimens based on simulations. Methods Patient data were collected from two centers in Canada, and a literature review was conducted to identify all published vancomycin popPK models for pediatric CF patients. External evaluation and simulations were performed according to patient and occasion of treatment. Results A total of 53 vancomycin concentrations were collected from six pediatric CF patients. Only two popPK models of vancomycin for pediatric CF patients were identified through the literature review. The external evaluation results for both centers combined revealed a population bias of 28.1% and an imprecision of 33.7%. A re-estimation of parameters was performed to improve predictive performance. The optimal initial dosing regimen was 15 mg/kg/dose administered every 6 hours according to the per occasion remodel. Conclusion The predictive performance and identified optimal initial dosing regimens associated with the model were different depending on the data used, showing external evaluation’s importance before implementing a model in clinical practice.
- 16 September 2024
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 49 (6) , 677-687
Vancomycin in Pediatric Patients with Cystic Fibrosis: Dose Optimization Using Population Pharmacokinetic Approach
Background An increase in Staphylococcus aureus infections has been reported in pediatric patients with cystic fibrosis (CF) over the last few years. This pathogen is commonly treated with vancomycin, an antibiotic for which therapeutic drug monitoring (TDM) is recommended. Updated guidelines were recently published regarding new targets of exposure for the TDM of vancomycin through a Bayesian approach, using population pharmacokinetic (popPK) models. Objectives This study aims to assess the predictive performance of vancomycin popPK models in pediatric patients with CF and to recommend optimal initial dosing regimens based on simulations. Methods Patient data were collected from two centers in Canada, and a literature review was conducted to identify all published vancomycin popPK models for pediatric CF patients. External evaluation and simulations were performed according to patient and occasion of treatment. Results A total of 53 vancomycin concentrations were collected from six pediatric CF patients. Only two popPK models of vancomycin for pediatric CF patients were identified through the literature review. The external evaluation results for both centers combined revealed a population bias of 28.1% and an imprecision of 33.7%. A re-estimation of parameters was performed to improve predictive performance. The optimal initial dosing regimen was 15 mg/kg/dose administered every 6 hours according to the per occasion remodel. Conclusion The predictive performance and identified optimal initial dosing regimens associated with the model were different depending on the data used, showing external evaluation’s importance before implementing a model in clinical practice.
- Open Access
- 24 August 2024
- Published by Wiley
External Evaluation of Intravenous Vancomycin Population Pharmacokinetics Models in Adults Receiving High-flux Intermittent Hemodialysis
Patients undergoing hemodialysis (HD) are at greater risk of methicillin-resistant Staphylococcus aureus infections requiring intravenous vancomycin. Close vancomycin therapeutic drug monitoring is warranted in HD patients as renal clearance is the primary elimination pathway. Clinically, population pharmacokinetics (popPK) model‐informed dosing is commonly used. This study aimed to perform an external evaluation of published vancomycin popPK models developed for adults undergoing high-flux intermittent HD, and to create a dosing nomogram derived from the best performing model. A literature review was conducted through PubMed and EMBASE to identify relevant popPK models. External dataset was collected retrospectively from patients of two healthcare centers in Quebec, Canada. Selected models were implemented in NONMEM (v7.5; ICON Development Solutions). Predictive performance was assessed through prediction and simulation-based diagnostics. Results analyses and graphical representations were then performed with Microsoft Excel (v16.69.1; Microsoft Office), R (v4.3.1; Posit Software) and R Studio (v1.4; Posit Software). A total of 2386 vancomycin concentrations were collected from 274 patients and 476 antibiotic courses. Four vancomycin popPK models were selected for evaluation. None of the models demonstrated overall satisfactory and clinically acceptable predictive performance. Nonetheless, Bae et al.’s model was the best performing with a MDPE of 16.25% and MDAPE of 34.66%. Different predictive performance was also observed for vancomycin concentrations from samples collected during and between HD sessions. All evaluated models presented poor overall predictive performance. Further studies are required, through existing popPK model parameters re-estimation or new model development, to adequately describe vancomycin pharmacokinetics for our high-flux intermittent HD patients’ cohort.
- 24 August 2024
- Published by Wiley
Open AccessExternal Evaluation of Intravenous Vancomycin Population Pharmacokinetics Models in Adults Receiving High-flux Intermittent Hemodialysis
Patients undergoing hemodialysis (HD) are at greater risk of methicillin-resistant Staphylococcus aureus infections requiring intravenous vancomycin. Close vancomycin therapeutic drug monitoring is warranted in HD patients as renal clearance is the primary elimination pathway. Clinically, population pharmacokinetics (popPK) model‐informed dosing is commonly used. This study aimed to perform an external evaluation of published vancomycin popPK models developed for adults undergoing high-flux intermittent HD, and to create a dosing nomogram derived from the best performing model. A literature review was conducted through PubMed and EMBASE to identify relevant popPK models. External dataset was collected retrospectively from patients of two healthcare centers in Quebec, Canada. Selected models were implemented in NONMEM (v7.5; ICON Development Solutions). Predictive performance was assessed through prediction and simulation-based diagnostics. Results analyses and graphical representations were then performed with Microsoft Excel (v16.69.1; Microsoft Office), R (v4.3.1; Posit Software) and R Studio (v1.4; Posit Software). A total of 2386 vancomycin concentrations were collected from 274 patients and 476 antibiotic courses. Four vancomycin popPK models were selected for evaluation. None of the models demonstrated overall satisfactory and clinically acceptable predictive performance. Nonetheless, Bae et al.’s model was the best performing with a MDPE of 16.25% and MDAPE of 34.66%. Different predictive performance was also observed for vancomycin concentrations from samples collected during and between HD sessions. All evaluated models presented poor overall predictive performance. Further studies are required, through existing popPK model parameters re-estimation or new model development, to adequately describe vancomycin pharmacokinetics for our high-flux intermittent HD patients’ cohort.
- Open Access
- 28 May 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (6) , 425-434
Vancomycin: An analysis and evaluation of eight population pharmacokinetic models for clinical application in general adult population
Introduction: Based on the recent guidelines for vancomycin therapeutic drug monitoring (TDM), the area under the curve to minimum inhibitory concentration ratio was to be employed combined with the usage of population pharmacokinetic (popPK) model for dosing adaptation. Yet, deploying these models in a clinical setting requires an external evaluation of their performance.Objectives: This study aimed to evaluate existing vancomycin popPK models from the literature for the use in TDM within the general patient population in a clinical setting.Methods: The models under external evaluation were chosen based on a review of literature covering vancomycin popPK models developed in general adult populations. Patients' data were collected from Charles‐Le Moyne Hospital (CLMH). The external evaluation was performed with NONMEM® (v7.5). Additional analyses such as evaluating the impact of number of samples on external evaluation, Bayesian forecasting, and a priori dosing regimen simulations were performed on the best performing model.Results: Eight popPK models were evaluated with an independent dataset that included 40 patients and 252 samples. The model developed by Goti and colleagues demonstrated superior performance in diagnostic plots and population predictive performance, with bias and inaccuracy values of 0.251% and 22.7%, respectively, and for individual predictive performance, bias and inaccuracy were −4.90% and 12.1%, respectively. When limiting the independent dataset to one or two samples per patient, the Goti model exhibited inadequate predictive performance for inaccuracy, with values exceeding 30%. Moreover, the Goti model is suitable for Bayesian forecasting with at least two samples as prior for the prediction of the next trough concentration. Furthermore, the vancomycin dosing regimen that would maximize therapeutic targets of area under the curve to minimum inhibitory concentration ratio (AUC24/MIC) and trough concentrations (Ctrough) for the Goti model was 20 mg/kg/dose twice daily.Conclusion: Considering the superior predictive performance and potential for Bayesian forecasting in the Goti model, future research aims to test its applicability in clinical settings at CLMH, both in a priori and a posteriori scenario.
- 28 May 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (6) , 425-434
Open AccessVancomycin: An analysis and evaluation of eight population pharmacokinetic models for clinical application in general adult population
Introduction: Based on the recent guidelines for vancomycin therapeutic drug monitoring (TDM), the area under the curve to minimum inhibitory concentration ratio was to be employed combined with the usage of population pharmacokinetic (popPK) model for dosing adaptation. Yet, deploying these models in a clinical setting requires an external evaluation of their performance.Objectives: This study aimed to evaluate existing vancomycin popPK models from the literature for the use in TDM within the general patient population in a clinical setting.Methods: The models under external evaluation were chosen based on a review of literature covering vancomycin popPK models developed in general adult populations. Patients' data were collected from Charles‐Le Moyne Hospital (CLMH). The external evaluation was performed with NONMEM® (v7.5). Additional analyses such as evaluating the impact of number of samples on external evaluation, Bayesian forecasting, and a priori dosing regimen simulations were performed on the best performing model.Results: Eight popPK models were evaluated with an independent dataset that included 40 patients and 252 samples. The model developed by Goti and colleagues demonstrated superior performance in diagnostic plots and population predictive performance, with bias and inaccuracy values of 0.251% and 22.7%, respectively, and for individual predictive performance, bias and inaccuracy were −4.90% and 12.1%, respectively. When limiting the independent dataset to one or two samples per patient, the Goti model exhibited inadequate predictive performance for inaccuracy, with values exceeding 30%. Moreover, the Goti model is suitable for Bayesian forecasting with at least two samples as prior for the prediction of the next trough concentration. Furthermore, the vancomycin dosing regimen that would maximize therapeutic targets of area under the curve to minimum inhibitory concentration ratio (AUC24/MIC) and trough concentrations (Ctrough) for the Goti model was 20 mg/kg/dose twice daily.Conclusion: Considering the superior predictive performance and potential for Bayesian forecasting in the Goti model, future research aims to test its applicability in clinical settings at CLMH, both in a priori and a posteriori scenario.
- Open Access
- 1 January 2024
- Published by Wiley in Critical Care Research and Practice
- Vol. 2024 (1) , 9757792
Serum Concentration at 24 h With Intensive Beta‐Lactam Therapy in Sepsis and Septic Shock: A Prospective Study
Introduction: Early administration of appropriate antibiotics has been shown to be among the most effective interventions to reduce mortality in septic patients. We evaluated the attainment of efficacy and safety targets at 24 h associated with the use of intensive beta‐lactam therapy in patients admitted to the intensive care unit for sepsis.Methods: This was a prospective study with patients who received beta‐lactams for sepsis or septic shock between February 2023 and September 2023. The antibiotic dose was unadjusted for renal function and administered by a loading dose followed by extended infusions, according to local practices. Blood samples were taken at the trough 24 h after the start of the beta‐lactam to obtain serum levels. These levels were compared to efficacy and innocuity thresholds found in the literature.Results: Among 36 included patients, all of them achieved serum concentrations above the minimum inhibitory concentration (MIC) for 100% of the therapeutic interval and 75% of them achieved serum concentrations above four times the MIC for 100% of the therapeutic interval. The predefined toxicity thresholds were reached by 8.3% of patients. Renal impairment was the factor most associated with the achievement of higher serum levels.Conclusion: Nonrenally adjusted doses of beta‐lactams administered by extended infusion showed good attainment of effective concentrations and few toxic concentrations in critically ill patients with sepsis or septic shock. Further studies are needed to better define the association between toxic concentrations and toxicity manifestations.
- 1 January 2024
- Published by Wiley in Critical Care Research and Practice
- Vol. 2024 (1) , 9757792
Open AccessSerum Concentration at 24 h With Intensive Beta‐Lactam Therapy in Sepsis and Septic Shock: A Prospective Study
Introduction: Early administration of appropriate antibiotics has been shown to be among the most effective interventions to reduce mortality in septic patients. We evaluated the attainment of efficacy and safety targets at 24 h associated with the use of intensive beta‐lactam therapy in patients admitted to the intensive care unit for sepsis.Methods: This was a prospective study with patients who received beta‐lactams for sepsis or septic shock between February 2023 and September 2023. The antibiotic dose was unadjusted for renal function and administered by a loading dose followed by extended infusions, according to local practices. Blood samples were taken at the trough 24 h after the start of the beta‐lactam to obtain serum levels. These levels were compared to efficacy and innocuity thresholds found in the literature.Results: Among 36 included patients, all of them achieved serum concentrations above the minimum inhibitory concentration (MIC) for 100% of the therapeutic interval and 75% of them achieved serum concentrations above four times the MIC for 100% of the therapeutic interval. The predefined toxicity thresholds were reached by 8.3% of patients. Renal impairment was the factor most associated with the achievement of higher serum levels.Conclusion: Nonrenally adjusted doses of beta‐lactams administered by extended infusion showed good attainment of effective concentrations and few toxic concentrations in critically ill patients with sepsis or septic shock. Further studies are needed to better define the association between toxic concentrations and toxicity manifestations.